| Prelude Fertility | 68.9 | 3 | 1 |
| Pacific Fertility Center Los Angeles (PFCLA) | 68.9 | 3 | 1 |
| Fertility and Sterility | 60.3 | 1 | 3 |
| Mayo Clinic | 60.0 | 4 | 0 |
| Cleveland Clinic | 60.0 | 4 | 0 |
| Human Resource Management Review | 60.0 | 4 | 0 |
| Colorado Center for Reproductive Medicine | 58.2 | 2 | 1 |
| Sher Fertility | 58.2 | 2 | 1 |
| National Institute for Occupational Safety and Health | 51.7 | 3 | 0 |
| Toxicological Sciences | 51.7 | 3 | 0 |
| Brain and Language | 51.7 | 3 | 0 |
| Virology | 51.7 | 3 | 0 |
| Applied Mathematics and Computation | 51.7 | 3 | 0 |
| Advances in Virus Research | 51.7 | 3 | 0 |
| Advances in Parasitology | 51.7 | 3 | 0 |
| Vital and health statistics. Series 21, Data on natality, marriage, and divorce | 51.7 | 3 | 0 |
| Vital and health statistics. Series 5, Comparative international vital and health statistics reports | 51.7 | 3 | 0 |
| Pacific Fertility Center | 51.7 | 3 | 0 |
| Office of Readiness and Response | 51.7 | 3 | 0 |
| American Society for Reproductive Medicine | 43.1 | 1 | 1 |
| Reproductive Medicine Associates of New York | 43.1 | 1 | 1 |
| Reproductive Medicine Associates of New Jersey | 43.1 | 1 | 1 |
| Reproductive Medicine Institute | 43.1 | 1 | 1 |
| Wave Motion | 41.0 | 2 | 0 |
| Ultrasonics Sonochemistry | 41.0 | 2 | 0 |
| Clinical Genitourinary Cancer | 41.0 | 2 | 0 |
| Journal of Economic Theory | 41.0 | 2 | 0 |
| Tetrahedron Letters | 41.0 | 2 | 0 |
| BioScience | 41.0 | 2 | 0 |
| Nuclear Physics | 41.0 | 2 | 0 |
| Trends in Cell Biology | 41.0 | 2 | 0 |
| Intelligence | 41.0 | 2 | 0 |
| Journal of Operations Management | 41.0 | 2 | 0 |
| Annals of Botany | 41.0 | 2 | 0 |
| Brachytherapy | 41.0 | 2 | 0 |
| Mechanisms of Ageing and Development | 41.0 | 2 | 0 |
| Trends in Cardiovascular Medicine | 41.0 | 2 | 0 |
| Seminars in Cancer Biology | 41.0 | 2 | 0 |
| Journal of Crystal Growth | 41.0 | 2 | 0 |
| Field Crops Research | 41.0 | 2 | 0 |
| Cardiovascular Pathology | 41.0 | 2 | 0 |
| Physica C | 41.0 | 2 | 0 |
| Computer Communications | 41.0 | 2 | 0 |
| Robotics and Autonomous Systems | 41.0 | 2 | 0 |
| Marine Micropaleontology | 41.0 | 2 | 0 |
| Comptes Rendus. Biologies | 41.0 | 2 | 0 |
| Mathematical Biosciences | 41.0 | 2 | 0 |
| International Journal of Medical Informatics | 41.0 | 2 | 0 |
| Postharvest Biology and Technology | 41.0 | 2 | 0 |
| Nuclear Physics A | 41.0 | 2 | 0 |
| Toxicology and Applied Pharmacology | 41.0 | 2 | 0 |
| Advances in Agronomy | 41.0 | 2 | 0 |
| Cancer Detection and Prevention | 41.0 | 2 | 0 |
| Cancer Radiothérapie | 41.0 | 2 | 0 |
| Epi Info | 41.0 | 2 | 0 |
| Microelectronic Engineering | 41.0 | 2 | 0 |
| Optical Switching and Networking | 41.0 | 2 | 0 |
| Journal of Communication Disorders | 41.0 | 2 | 0 |
| Biological Journal of the Linnean Society | 41.0 | 2 | 0 |
| Agricultural Systems | 41.0 | 2 | 0 |
| Applied Catalysis A: General | 41.0 | 2 | 0 |
| Applied Clay Science | 41.0 | 2 | 0 |
| International Review of Cytology | 41.0 | 2 | 0 |
| International Journal of Obstetric Anesthesia | 41.0 | 2 | 0 |
| Nuclear Physics B | 41.0 | 2 | 0 |
| Annales pharmaceutiques françaises | 41.0 | 2 | 0 |
| Coordination Chemistry Reviews | 41.0 | 2 | 0 |
| Food Chemistry | 41.0 | 2 | 0 |
| Journal of Molecular Structure | 41.0 | 2 | 0 |
| Journal of the American Society for Mass Spectrometry | 41.0 | 2 | 0 |
| Electrochemistry Communications | 41.0 | 2 | 0 |
| Fuel Processing Technology | 41.0 | 2 | 0 |
| Advances in Cancer Research | 41.0 | 2 | 0 |
| Journal of Fluorine Chemistry | 41.0 | 2 | 0 |
| Journal of Nutrition | 41.0 | 2 | 0 |
| Journal of Pharmaceutical Sciences | 41.0 | 2 | 0 |
| Microporous and Mesoporous Materials | 41.0 | 2 | 0 |
| Progress in Solid State Chemistry | 41.0 | 2 | 0 |
| Radiation Physics and Chemistry | 41.0 | 2 | 0 |
| Vibrational Spectroscopy | 41.0 | 2 | 0 |
| Physiology & Behavior | 41.0 | 2 | 0 |
| Vacuum | 41.0 | 2 | 0 |
| Computers and Electronics in Agriculture | 41.0 | 2 | 0 |
| Advances in Mathematics | 41.0 | 2 | 0 |
| American Journal of Preventive Medicine | 41.0 | 2 | 0 |
| Brain Research | 41.0 | 2 | 0 |
| British Journal of Dermatology | 41.0 | 2 | 0 |
| China Economic Review | 41.0 | 2 | 0 |
| Cultural Diversity and Ethnic Minority Psychology | 41.0 | 2 | 0 |
| Duke University Health System | 41.0 | 2 | 0 |
| Early Childhood Research Quarterly | 41.0 | 2 | 0 |
| Experimental Hematology | 41.0 | 2 | 0 |
| Geochimica et Cosmochimica Acta | 41.0 | 2 | 0 |
| The Journal of Biochemistry | 41.0 | 2 | 0 |
| Journal of Memory and Language | 41.0 | 2 | 0 |
| Journal of Second Language Writing | 41.0 | 2 | 0 |
| Journal of Sound and Vibration | 41.0 | 2 | 0 |
| Journal of the Academy of Nutrition and Dietetics | 41.0 | 2 | 0 |
| Laboratory Investigation | 41.0 | 2 | 0 |
| Learning and Individual Differences | 41.0 | 2 | 0 |
| Magnetic Resonance Imaging | 41.0 | 2 | 0 |
| Museum Management and Curatorship | 41.0 | 2 | 0 |
| Personality and Individual Differences | 41.0 | 2 | 0 |
| Preventing Chronic Disease | 41.0 | 2 | 0 |
| Quaternary Research | 41.0 | 2 | 0 |
| Transplantation Proceedings | 41.0 | 2 | 0 |
| Finite Elements in Analysis and Design | 41.0 | 2 | 0 |
| Linear Algebra and its Applications | 41.0 | 2 | 0 |
| Annales de l'Institut Henri Poincare C | 41.0 | 2 | 0 |
| Applied Mathematics Letters | 41.0 | 2 | 0 |
| Applied Numerical Mathematics | 41.0 | 2 | 0 |
| Current Opinion in Genetics & Development | 41.0 | 2 | 0 |
| Journal of Fluency Disorders | 41.0 | 2 | 0 |
| Nonlinear Analysis | 41.0 | 2 | 0 |
| Nuclear Instruments & Methods in Physics Research B | 41.0 | 2 | 0 |
| Seminars in Cell & Developmental Biology | 41.0 | 2 | 0 |
| Systems & Control Letters | 41.0 | 2 | 0 |
| NeuroToxicology | 41.0 | 2 | 0 |
| Differential Geometry and its Applications | 41.0 | 2 | 0 |
| Journal of Combinatorial Theory, Series B | 41.0 | 2 | 0 |
| Journal of Mathematical Analysis and Applications | 41.0 | 2 | 0 |
| Journal of Web Semantics | 41.0 | 2 | 0 |
| Pathophysiology | 41.0 | 2 | 0 |
| BJOG: an International Journal of Obstetrics and Gynaecology | 41.0 | 2 | 0 |
| Archives of Gerontology and Geriatrics | 41.0 | 2 | 0 |
| Cryptogamie Bryologie | 41.0 | 2 | 0 |
| Advances in Marine Biology | 41.0 | 2 | 0 |
| BBA: Molecular Basis of Disease | 41.0 | 2 | 0 |
| Global Finance Journal | 41.0 | 2 | 0 |
| Advances in Carbohydrate Chemistry and Biochemistry | 41.0 | 2 | 0 |
| Brain and Development | 41.0 | 2 | 0 |
| Cryptogamie Algologie | 41.0 | 2 | 0 |
| Aggression and Violent Behavior | 41.0 | 2 | 0 |
| Archives of Clinical Neuropsychology | 41.0 | 2 | 0 |
| Pediatric Neurology | 41.0 | 2 | 0 |
| General Hospital Psychiatry | 41.0 | 2 | 0 |
| Comparative Immunology, Microbiology & Infectious Diseases | 41.0 | 2 | 0 |
| Advances in Applied Microbiology | 41.0 | 2 | 0 |
| Optometry - Journal of the American Optometric Association | 41.0 | 2 | 0 |
| I C E S Journal of Marine Science | 41.0 | 2 | 0 |
| Journal of Policy Modeling | 41.0 | 2 | 0 |
| Best Practice and Research: Clinical Gastroenterology | 41.0 | 2 | 0 |
| International Journal of Law and Psychiatry | 41.0 | 2 | 0 |
| Prostaglandins and Other Lipid Mediators | 41.0 | 2 | 0 |
| Building and Environment | 41.0 | 2 | 0 |
| Industrial Marketing Management | 41.0 | 2 | 0 |
| Meat Science | 41.0 | 2 | 0 |
| Research in Organizational Behavior | 41.0 | 2 | 0 |
| Fish and Shellfish Immunology | 41.0 | 2 | 0 |
| Journal of Immunological Methods | 41.0 | 2 | 0 |
| European Journal of Cardiovascular Nursing | 41.0 | 2 | 0 |
| Human Pathology | 41.0 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology | 41.0 | 2 | 0 |
| The History of the Family | 41.0 | 2 | 0 |
| Journal of Environmental Management | 41.0 | 2 | 0 |
| Insight | 41.0 | 2 | 0 |
| Business Horizons | 41.0 | 2 | 0 |
| Computers in Human Behavior | 41.0 | 2 | 0 |
| Government Information Quarterly | 41.0 | 2 | 0 |
| Linguistics and Education | 41.0 | 2 | 0 |
| Cryptogamie Mycologie | 41.0 | 2 | 0 |
| Behaviour Research and Therapy | 41.0 | 2 | 0 |
| Advances in Botanical Research | 41.0 | 2 | 0 |
| Comptes Rendus. Géoscience | 41.0 | 2 | 0 |
| Policy and Society | 41.0 | 2 | 0 |
| Socio-Economic Planning Sciences | 41.0 | 2 | 0 |
| Organizational Dynamics | 41.0 | 2 | 0 |
| The American Journal of Surgery | 41.0 | 2 | 0 |
| Clinical Neurophysiology | 41.0 | 2 | 0 |
| Ocean Engineering | 41.0 | 2 | 0 |
| International Review of Law and Economics | 41.0 | 2 | 0 |
| Nuclear Physics B - Proceedings Supplements | 41.0 | 2 | 0 |
| Revue Europeene de Psychologie Appliquee | 41.0 | 2 | 0 |
| Computers & Graphics | 41.0 | 2 | 0 |
| Journal of African Earth Sciences | 41.0 | 2 | 0 |
| Annual Reports in Medicinal Chemistry | 41.0 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part D: Genomics and Proteomics | 41.0 | 2 | 0 |
| European Journal of Mechanics A - Solids | 41.0 | 2 | 0 |
| Computers and Composition | 41.0 | 2 | 0 |
| Review of Financial Economics | 41.0 | 2 | 0 |
| Maturitas | 41.0 | 2 | 0 |
| Financial Services Review | 41.0 | 2 | 0 |
| Mechanics Research Communications | 41.0 | 2 | 0 |
| Journal of Cultural Heritage | 41.0 | 2 | 0 |
| Clinical Imaging | 41.0 | 2 | 0 |
| Journal of Environmental Sciences | 41.0 | 2 | 0 |
| Journal of Clinical Lipidology | 41.0 | 2 | 0 |
| Journal of Orthopaedics, Trauma and Rehabilitation | 41.0 | 2 | 0 |
| Ticks and Tick-borne Diseases | 41.0 | 2 | 0 |
| The Electricity Journal | 41.0 | 2 | 0 |
| Social Science Research | 41.0 | 2 | 0 |
| Archives of Cardiovascular Diseases Supplements | 41.0 | 2 | 0 |
| National Survey of Family Growth | 41.0 | 2 | 0 |
| National Vital Statistics System | 41.0 | 2 | 0 |
| NIOSH Power Tools Database | 41.0 | 2 | 0 |
| UCLA Health System | 41.0 | 2 | 0 |
| NewYork-Presbyterian Westchester | 41.0 | 2 | 0 |
| Advances in Nutrition | 41.0 | 2 | 0 |
| Morbidity and Mortality Weekly Report: Recommendations and Reports | 41.0 | 2 | 0 |
| Filtration & Separation | 41.0 | 2 | 0 |
| Fundamental and Applied Toxicology | 41.0 | 2 | 0 |
| Journal of the Less Common Metals | 41.0 | 2 | 0 |
| Scripta Metallurgica | 41.0 | 2 | 0 |
| Diseases of the chest | 41.0 | 2 | 0 |
| Chemical health & safety American Chemical Society, Division of Chemical Health and Safety | 41.0 | 2 | 0 |
| Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo | 41.0 | 2 | 0 |
| Behavioral Biology | 41.0 | 2 | 0 |
| Cell Biology International Reports | 41.0 | 2 | 0 |
| Vital & health statistics. Series 3, Analytical and epidemiological studies | 41.0 | 2 | 0 |
| Prostate international | 41.0 | 2 | 0 |
| Clinical neurosurgery | 41.0 | 2 | 0 |
| The Lancet Psychiatry | 41.0 | 2 | 0 |
| Advances in food research | 41.0 | 2 | 0 |
| Science in China. Series B, Chemistry, life sciences & earth sciences | 41.0 | 2 | 0 |
| Genetic analysis, techniques and applications | 41.0 | 2 | 0 |
| Journal of the American Pharmaceutical Association | 41.0 | 2 | 0 |
| Vital and health statistics. Series 3, Analytical studies | 41.0 | 2 | 0 |
| Vital and health statistics. Ser. 4, Documents and committee reports | 41.0 | 2 | 0 |
| Vital and health statistics. Series 13, Data from the National Health Survey | 41.0 | 2 | 0 |
| Journal of epilepsy | 41.0 | 2 | 0 |
| Ethology and sociobiology | 41.0 | 2 | 0 |
| Aging trends (Hyattsville, Md.) | 41.0 | 2 | 0 |
| Clinical microbiology newsletter | 41.0 | 2 | 0 |
| NCHS data brief | 41.0 | 2 | 0 |
| Journal of Verbal Learning and Verbal Behavior | 41.0 | 2 | 0 |
| Paediatrics and Child Health | 41.0 | 2 | 0 |
| The Lancet: Diabetes & Endocrinology | 41.0 | 2 | 0 |
| Sexual medicine | 41.0 | 2 | 0 |
| Avian Research | 41.0 | 2 | 0 |
| Sexual medicine reviews | 41.0 | 2 | 0 |
| Cell Chemical Biology | 41.0 | 2 | 0 |
| MMWR supplements | 41.0 | 2 | 0 |
| Operative neurosurgery (Hagerstown, Md.) | 41.0 | 2 | 0 |
| Clinical neurophysiology practice | 41.0 | 2 | 0 |
| Information and control | 41.0 | 2 | 0 |
| Studies in Logic and the Foundations of Mathematics | 41.0 | 2 | 0 |
| Computing systems in engineering : an international journal | 41.0 | 2 | 0 |
| National Center for Emerging and Zoonotic Infectious Diseases | 41.0 | 2 | 0 |
| Division of Parasitic Diseases and Malaria | 41.0 | 2 | 0 |
| Fertility Center of San Antonio | 41.0 | 2 | 0 |
| San Diego Fertility Center | 41.0 | 2 | 0 |
| Chronic Disease Prevention and Health Promotion | 41.0 | 2 | 0 |
| Fertility Center of Las Vegas | 41.0 | 2 | 0 |
| Shady Grove Fertility Center | 41.0 | 2 | 0 |
| Cooper Health System | 41.0 | 2 | 0 |
| The Journal of Finance and Data Science | 41.0 | 2 | 0 |
| New Hope Fertility Center | 41.0 | 2 | 0 |
| Johns Hopkins Medicine | 41.0 | 2 | 0 |
| Chronic Diseases and Translational Medicine | 41.0 | 2 | 0 |
| World Journal of Otorhinolaryngology-Head and Neck Surgery | 41.0 | 2 | 0 |
| Journal of Urban Management | 41.0 | 2 | 0 |
| Journal of Asian Ceramic Societies | 41.0 | 2 | 0 |
| Climate Risk Management | 41.0 | 2 | 0 |
| Information Processing in Agriculture | 41.0 | 2 | 0 |
| Advances in Inorganic Chemistry and Radiochemistry | 41.0 | 2 | 0 |
| Fish Physiology | 41.0 | 2 | 0 |
| Computer Vision, Graphics, and Image Processing | 41.0 | 2 | 0 |
| Network Security | 41.0 | 2 | 0 |
| Inorganic and Nuclear Chemistry Letters | 41.0 | 2 | 0 |
| Inorganica Chimica Acta Reviews | 41.0 | 2 | 0 |
| Information Storage and Retrieval | 41.0 | 2 | 0 |
| Biometric Technology Today | 41.0 | 2 | 0 |
| Membrane Technology | 41.0 | 2 | 0 |
| Filtration Industry Analyst | 41.0 | 2 | 0 |
| Fuel Cells Bulletin | 41.0 | 2 | 0 |
| Journal of Patient Safety & Infection Control | 41.0 | 2 | 0 |
| Pump Industry Analyst | 41.0 | 2 | 0 |
| Space Research Today | 41.0 | 2 | 0 |
| World Pumps | 41.0 | 2 | 0 |
| Biology Methods and Protocols | 41.0 | 2 | 0 |
| Christopher R. Conley | 41.0 | 2 | 0 |
| assisted reproductive technology | 40.0 | 0 | 4 |
| Embryo transfer by reproductive endocrinology fellows vs attending physicians: are live birth rates comparable? | 40.0 | 0 | 4 |
| fertility clinic | 34.5 | 0 | 3 |
| Money Management International | 34.5 | 0 | 3 |
| Impact of men's dairy intake on assisted reproductive technology outcomes among couples attending a fertility clinic | 34.5 | 0 | 3 |
| Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation-intrauterine insemination | 34.5 | 0 | 3 |
| A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey | 34.5 | 0 | 3 |
| Preimplantation genetic testing: a Practice Committee opinion | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 34.5 | 0 | 3 |
| Elective single-embryo transfer | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinical-assisted reproduction: a committee opinion | 34.5 | 0 | 3 |
| Embryo transfer techniques: an American Society for Reproductive Medicine survey of current Society for Assisted Reproductive Technology practices | 34.5 | 0 | 3 |
| Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? | 34.5 | 0 | 3 |
| Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility. | 34.5 | 0 | 3 |
| Impact of single embryo transfer policy on perinatal outcomes in fresh and frozen cycles—analysis of the Japanese Assisted Reproduction Technology registry between 2007 and 2012 | 34.5 | 0 | 3 |
| Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials | 34.5 | 0 | 3 |
| Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment? | 34.5 | 0 | 3 |
| There is no evidence that the time from egg retrieval to embryo transfer affects live birth rates in a freeze-all strategy | 34.5 | 0 | 3 |
| Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET | 34.5 | 0 | 3 |
| Single embryo implantation per IVF cycle: the answer to every request for assisted reproduction? | 34.5 | 0 | 3 |
| The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling | 34.5 | 0 | 3 |
| Elective single embryo transfer in women less than age 38 years reduces multiple birth rates, but not live birth rates, in United States fertility clinics | 34.5 | 0 | 3 |
| Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study | 34.5 | 0 | 3 |
| Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 34.5 | 0 | 3 |
| Assessment of United States fertility clinic websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 34.5 | 0 | 3 |
| Preimplantation genetic testing: a Practice Committee opinion | 34.5 | 0 | 3 |
| Processing of semen by density gradient centrifugation selects spermatozoa with longer telomeres for assisted reproduction techniques | 34.5 | 0 | 3 |
| The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion | 34.5 | 0 | 3 |
| Blastocyst culture and transfer in clinically assisted reproduction: a committee opinion | 34.5 | 0 | 3 |
| Androgenicity and fertility treatment in women with unexplained infertility | 34.5 | 0 | 3 |
| Evaluating the benefit of measuring serum progesterone prior to the administration of HCG: effect of the duration of late-follicular elevated progesterone following ovarian stimulation on fresh embryo transfer live birth rates | 34.5 | 0 | 3 |
| Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility | 34.5 | 0 | 3 |
| Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes | 34.5 | 0 | 3 |
| Outcome of mock embryo transfer before the first IVF cycle: A randomized control trial | 34.5 | 0 | 3 |
| in vitro fertilization | 27.3 | 0 | 2 |
| Journal of Assisted Reproduction and Genetics | 27.3 | 0 | 2 |
| Financial Counseling and Planning | 27.3 | 0 | 2 |
| Reproductive Medicine and Biology | 27.3 | 0 | 2 |
| Naprotechnology | 27.3 | 0 | 2 |
| Semen analysis and fertility assessment in rabbits: statistical power and design considerations for toxicology studies | 27.3 | 0 | 2 |
| Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer) | 27.3 | 0 | 2 |
| Post-embryo transfer interventions for assisted reproduction technology cycles | 27.3 | 0 | 2 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 27.3 | 0 | 2 |
| Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 27.3 | 0 | 2 |
| Soft versus firm embryo transfer catheters for assisted reproductive technology | 27.3 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles | 27.3 | 0 | 2 |
| Journal of Experimental & Clinical Assisted Reproduction: shaping the future of research and practice in reproductive endocrinology/infertility | 27.3 | 0 | 2 |
| The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment | 27.3 | 0 | 2 |
| Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology | 27.3 | 0 | 2 |
| <i>In vitro</i> fertilization in Japan — Early days of <i>in vitro</i> fertilization and embryo transfer and future prospects for assisted reproductive technology — | 27.3 | 0 | 2 |
| Q28344605 | 27.3 | 0 | 2 |
| Fertility-related quality of life from two RCT cohorts with infertility: unexplained infertility and polycystic ovary syndrome. | 27.3 | 0 | 2 |
| Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility | 27.3 | 0 | 2 |
| Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics | 27.3 | 0 | 2 |
| Predictors of participant retention in infertility treatment trials | 27.3 | 0 | 2 |
| Outcomes and Recommendations of an Indian Expert Panel for Improved Practice in Controlled Ovarian Stimulation for Assisted Reproductive Technology. | 27.3 | 0 | 2 |
| Risk of major congenital anomalies after assisted hatching: analysis of three-year data from the national assisted reproduction registry in Japan | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A committee opinion | 27.3 | 0 | 2 |
| Pregnancy outcomes after assisted reproductive technology | 27.3 | 0 | 2 |
| Human spermatozoa ultrastructure assessment in the infertility treatment by assisted reproduction technique | 27.3 | 0 | 2 |
| Increasing and decreasing factors of hope in infertile women with failure in infertility treatment: A phenomenology study | 27.3 | 0 | 2 |
| The status of assisted reproductive technology in Korea in 2012 | 27.3 | 0 | 2 |
| Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis. | 27.3 | 0 | 2 |
| Impact of Endometrial Preparation Protocols for Frozen Embryo Transfer on Live Birth Rates | 27.3 | 0 | 2 |
| Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues | 27.3 | 0 | 2 |
| Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction. | 27.3 | 0 | 2 |
| The incidence of monozygotic twinning in assisted reproductive technology: Analysis based on results from the 2010 Japanese ART national registry | 27.3 | 0 | 2 |
| Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles | 27.3 | 0 | 2 |
| A randomized clinical trial to determine optimal infertility treatment in older couples: the Forty and Over Treatment Trial (FORT-T) | 27.3 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. | 27.3 | 0 | 2 |
| Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer | 27.3 | 0 | 2 |
| The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer | 27.3 | 0 | 2 |
| Is tubal embryo transfer of any value? A meta-analysis and comparison with the Society for Assisted Reproductive Technology database | 27.3 | 0 | 2 |
| The inSIGHT study: costs and effects of routine hysteroscopy prior to a first IVF treatment cycle. A randomised controlled trial | 27.3 | 0 | 2 |
| Factors influencing pregnancy rates with a combined clomiphene citrate/gonadotropin protocol for non-assisted reproductive technology fertility treatment | 27.3 | 0 | 2 |
| Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction | 27.3 | 0 | 2 |
| Effect of cell phone usage on semen analysis in men attending infertility clinic: an observational study | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons: a committee opinion | 27.3 | 0 | 2 |
| Risk of breast cancer following fertility treatment—A registry based cohort study of parous women in Norway | 27.3 | 0 | 2 |
| Semen Analysis: A Review of Samples from 225 Men Seen at an Infertility Clinic | 27.3 | 0 | 2 |
| A healthy delivery of twins by assisted reproduction followed by preimplantation genetic screening in a woman with X-linked dominant incontinentia pigmenti | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 27.3 | 0 | 2 |
| Prognostic value of first IVF cycle on success of a subsequent cycle | 27.3 | 0 | 2 |
| Hysteroscopy prior to the first IVF cycle: A systematic review and meta-analysis | 27.3 | 0 | 2 |
| Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients | 27.3 | 0 | 2 |
| The use of luteinising hormone releasing hormone agonists for ovarian stimulation in assisted reproductive technology | 27.3 | 0 | 2 |
| Application of a validated prediction model for in vitro fertilization: comparison of live birth rates and multiple birth rates with 1 embryo transferred over 2 cycles vs 2 embryos in 1 cycle | 27.3 | 0 | 2 |
| Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: Case report | 27.3 | 0 | 2 |
| Choice of ovarian stimulation regimens in assisted reproduction: finding the thread in the gonadotropin maze | 27.3 | 0 | 2 |
| The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility | 27.3 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction?: challenges in measuring and reporting success rates for assisted reproductive technology treatments: what is optimal? | 27.3 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction? Redefining success in the context of elective single embryo transfer: evidence, intuition and financial reality | 27.3 | 0 | 2 |
| Effectiveness and treatment for unexplained infertility | 27.3 | 0 | 2 |
| Patients undergoing frozen-thawed embryo transfer have similar live birth rates in spontaneous and artificial cycles | 27.3 | 0 | 2 |
| The best infertility treatment for vasectomized men: assisted reproduction or vasectomy reversal? | 27.3 | 0 | 2 |
| Effect of Embryo Banking on U.S. National Assisted Reproductive Technology Live Birth Rates | 27.3 | 0 | 2 |
| Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation | 27.3 | 0 | 2 |
| Gonadotrophin ovarian stimulation and intrauterine insemination for unexplained infertility | 27.3 | 0 | 2 |
| Minimal ovarian stimulation combined with elective single embryo transfer policy: age-specific results of a large, single-centre, Japanese cohort | 27.3 | 0 | 2 |
| The association of serum estradiol level with outcomes of clomiphene citrate/human menopausal gonadotropin ovarian stimulation for in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Effect of endometrial biopsy on intrauterine insemination outcome in controlled ovarian stimulation cycle | 27.3 | 0 | 2 |
| Sperm chromatin structure assay results in Nigerian men with unexplained infertility | 27.3 | 0 | 2 |
| Embryo transfer practices and multiple births resulting from assisted reproductive technology: an opportunity for prevention | 27.3 | 0 | 2 |
| Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis | 27.3 | 0 | 2 |
| Conservative management versus aspiration of functional ovarian cysts before ovarian stimulation for assisted reproduction | 27.3 | 0 | 2 |
| Treatment policy after poor fertilization in the first IVF cycle | 27.3 | 0 | 2 |
| Firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis using direct and adjusted indirect comparisons | 27.3 | 0 | 2 |
| Embryo transfer in days 2 to 4 following intracytoplasmic sperm injection: a prospective cohort study | 27.3 | 0 | 2 |
| Age-Related Normogram for Ovarian Antral Follicle Count in Women with Polycystic Ovary Syndrome and Comparison with Age Matched Controls Using Magnetic Resonance Imaging | 27.3 | 0 | 2 |
| Genetic considerations related to intracytoplasmic sperm injection (ICSI). | 27.3 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI). | 27.3 | 0 | 2 |
| Comparing blastocyst quality and live birth rates of intravaginal culture using INVOcell™ to traditional in vitro incubation in a randomized open-label prospective controlled trial | 27.3 | 0 | 2 |
| Computer-assisted semen analysis systems: comparison with routine evaluation and prognostic value in male fertility and assisted reproduction | 27.3 | 0 | 2 |
| Current status of assisted reproductive technology in Korea, 2011 | 27.3 | 0 | 2 |
| Reluctance of medical professionals in adopting natural-cycle and minimal ovarian stimulation protocols in human clinical assisted reproduction | 27.3 | 0 | 2 |
| Use of letrozole in assisted reproduction: a systematic review and meta-analysis. | 27.3 | 0 | 2 |
| A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology | 27.3 | 0 | 2 |
| The significance of serum anti-Müllerian hormone (AMH) levels in patients over age 40 in first IVF treatment | 27.3 | 0 | 2 |
| Estimating rates of multiple gestation pregnancies: sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial | 27.3 | 0 | 2 |
| Anti-mullerian hormone and antral follicle count as predictors of ovarian response in assisted reproduction | 27.3 | 0 | 2 |
| Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles | 27.3 | 0 | 2 |
| Endometrial morphology and modulation of hormone receptors during ovarian stimulation for assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Optimizing natural fertility | 27.3 | 0 | 2 |
| Assisted reproductive technology use, embryo transfer practices, and birth outcomes after infertility insurance mandates: New Jersey and Connecticut | 27.3 | 0 | 2 |
| Endometrial signaling pathways during ovarian stimulation for assisted reproduction technology | 27.3 | 0 | 2 |
| Costs of achieving live birth from assisted reproductive technology: a comparison of sequential single and double embryo transfer approaches | 27.3 | 0 | 2 |
| Validation of infertility treatment and assisted reproductive technology use on the birth certificate in eight states | 27.3 | 0 | 2 |
| Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms | 27.3 | 0 | 2 |
| Attitudes towards single embryo transfer, twin and higher order pregnancies in patients undergoing infertility treatment: a review | 27.3 | 0 | 2 |
| Human immunodeficiency virus and infertility treatment | 27.3 | 0 | 2 |
| Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction | 27.3 | 0 | 2 |
| Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature | 27.3 | 0 | 2 |
| Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. | 27.3 | 0 | 2 |
| Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion | 27.3 | 0 | 2 |
| In vitro maturation: a committee opinion | 27.3 | 0 | 2 |
| The wobbly evidence base of reproductive medicine | 27.3 | 0 | 2 |
| Body mass index in relation to semen quality and reproductive hormones in New Zealand men: a cross-sectional study in fertility clinics | 27.3 | 0 | 2 |
| Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis of randomized controlled trials | 27.3 | 0 | 2 |
| Misconduct in third-party assisted reproduction: a committee opinion | 27.3 | 0 | 2 |
| VACTERL association with hydrocephalus in a fetus conceived by in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Cryopreservation and delayed embryo transfer-assisted reproductive technology registry and reporting implications | 27.3 | 0 | 2 |
| Role of assisted hatching in in vitro fertilization: a guideline | 27.3 | 0 | 2 |
| Recommended practices for the management of embryology, andrology, and endocrinology laboratories: a committee opinion | 27.3 | 0 | 2 |
| Assisted reproductive technology - IVF treatment in Ireland: A study of couples with successful outcomes | 27.3 | 0 | 2 |
| Does weight loss in overweight or obese women improve fertility treatment outcomes? A systematic review | 27.3 | 0 | 2 |
| Methods employed to overcome difficult embryo transfer during assisted reproduction treatment | 27.3 | 0 | 2 |
| Role of tubal surgery in the era of assisted reproductive technology: a committee opinion | 27.3 | 0 | 2 |
| A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone | 27.3 | 0 | 2 |
| Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen–thawed embryo transfer in normal responders | 27.3 | 0 | 2 |
| Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients | 27.3 | 0 | 2 |
| Role of the mental health professional in education and support of the medical staff | 27.3 | 0 | 2 |
| Subclinical hypothyroidism in the infertile female population: a guideline | 27.3 | 0 | 2 |
| Comparison of neonatal outcomes following progesterone use during ovarian stimulation with frozen-thawed embryo transfer | 27.3 | 0 | 2 |
| Assisted reproductive technology in Australia and New Zealand: cumulative live birth rates as measures of success | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Lesbian, gay, bisexual, transgender content on reproductive endocrinology and infertility clinic websites | 27.3 | 0 | 2 |
| The effect of peri-implantation administration of uterine relaxing agents in assisted reproduction treatment cycles: a systematic review and meta-analysis | 27.3 | 0 | 2 |
| Maternal Racial and Ethnic Disparities in Neonatal Birth Outcomes With and Without Assisted Reproduction | 27.3 | 0 | 2 |
| Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility | 27.3 | 0 | 2 |
| Factors predicting double embryo implantation following double embryo transfer in assisted reproductive technology: implications for elective single embryo transfer | 27.3 | 0 | 2 |
| Guidance on the limits to the number of embryos to transfer: a committee opinion | 27.3 | 0 | 2 |
| Perinatal outcomes among singletons after assisted reproductive technology with single-embryo or double-embryo transfer versus no assisted reproductive technology | 27.3 | 0 | 2 |
| Embryo transfer simulation improves pregnancy rates and decreases time to proficiency in Reproductive Endocrinology and Infertility fellow embryo transfers | 27.3 | 0 | 2 |
| Practice patterns, satisfaction, and demographics of reproductive endocrinologists: results of the 2014 Society for Reproductive Endocrinology and Infertility Workforce Survey | 27.3 | 0 | 2 |
| The role of steroid hormone supplementation in non-assisted reproductive technology treatments for unexplained infertility | 27.3 | 0 | 2 |
| Performing the embryo transfer: a guideline | 27.3 | 0 | 2 |
| Effect of smoking on ovarian reserve and ovarian stimulation in in- vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Population-based Semen Analysis Results and Fertility Among Patients With Inflammatory Bowel Disease: Results From Subfertility Health Assisted Reproduction and the Environment (SHARE) Study | 27.3 | 0 | 2 |
| Assisted reproductive technology: public funding and the voluntary shift to single embryo transfer in Australia | 27.3 | 0 | 2 |
| Couples with unexplained subfertility and unfavorable prognosis: a randomized pilot trial comparing the effectiveness of in vitro fertilization with elective single embryo transfer versus intrauterine insemination with controlled ovarian stimulation | 27.3 | 0 | 2 |
| Ovarian stimulation with clomiphene and/or human menopausal gonadotropin (HMG) for in vitro fertilization (IVF) and embryo transfer (ET). | 27.3 | 0 | 2 |
| Assisted reproductive techniques in Latin America: the Latin American Registry, 2013 | 27.3 | 0 | 2 |
| Assisted reproductive medicine in Poland --Fertility and Sterility Special Interest Group of the Polish Gynaecological Society (SPiN PTG) 2012 report | 27.3 | 0 | 2 |
| Endometrial thickness significantly affects clinical pregnancy and live birth rates in frozen-thawed embryo transfer cycles | 27.3 | 0 | 2 |
| Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study | 27.3 | 0 | 2 |
| Determining the need for rescue intracytoplasmic sperm injection in partial fertilisation failure during a conventional IVF cycle | 27.3 | 0 | 2 |
| Pain during embryo transfer is independently associated with clinical pregnancy in fresh/frozen assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Catastrophic payment for assisted reproduction techniques with conventional ovarian stimulation in the public health sector of South Africa: frequency and coping strategies | 27.3 | 0 | 2 |
| Assisted reproduction policies in Israel: a retrospective analysis of in vitro fertilization–embryo transfer | 27.3 | 0 | 2 |
| How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries? | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: a committee opinion | 27.3 | 0 | 2 |
| Is there an effect of thyroid autoimmunity on the outcomes of assisted reproduction? | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile virus | 27.3 | 0 | 2 |
| Predictive values of anti-müllerian hormone, antral follicle count and ovarian response prediction index (ORPI) for assisted reproductive technology outcomes | 27.3 | 0 | 2 |
| Live birth rates are satisfactory following multiple IVF treatment cycles in poor prognosis patients. | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile virus | 27.3 | 0 | 2 |
| Risk of ectopic pregnancy is linked to endometrial thickness in a retrospective cohort study of 8120 assisted reproduction technology cycles | 27.3 | 0 | 2 |
| American Society for Reproductive Medicine/Society for Assisted Reproductive Technology position statement on West Nile Virus | 27.3 | 0 | 2 |
| Cumulative number and morphological score of embryos resulting in success: realistic expectations from in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Physical health of singleton children born after frozen embryo transfer using slow freezing: a 3-year follow-up study | 27.3 | 0 | 2 |
| Cycle-to-cycle variation in utero-ovarian hemodynamic indices in ovarian stimulation and natural cycles of the same women and its effect on the outcome of assisted reproduction treatment. | 27.3 | 0 | 2 |
| The relationship between the changes in the level of progesterone and the outcome ofin vitrofertilization-embryo transfer | 27.3 | 0 | 2 |
| Luteinizing hormone-releasing hormone agonists for ovarian stimulation in assisted reproduction | 27.3 | 0 | 2 |
| Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction | 27.3 | 0 | 2 |
| Position on reproductive donors and smallpox vaccine: a committee opinion | 27.3 | 0 | 2 |
| Ovarian stimulation for assisted reproduction | 27.3 | 0 | 2 |
| Hormonal and Clinical Predictors for Post-egg Retrieval Pain in Women Undergoing Assisted Reproductive Technology Procedures. | 27.3 | 0 | 2 |
| Current differences and consequences of legislation on practice of assisted reproductive technology in the Nordic countries. The Nordic Committee on Assisted Reproduction of the Scandinavian Federation of Societies of Obstetrics and Gynecology | 27.3 | 0 | 2 |
| Mole modifications following controlled ovarian stimulation for assisted reproduction technologies | 27.3 | 0 | 2 |
| Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles | 27.3 | 0 | 2 |
| Human immunodeficiency virus (HIV) and infertility treatment: a committee opinion | 27.3 | 0 | 2 |
| Ovarian stimulation in assisted reproduction. | 27.3 | 0 | 2 |
| Safety in reproductive medicine: breadth, depth and discovery | 27.3 | 0 | 2 |
| Cumulative live birth rates after fresh and vitrified cleavage-stage versus blastocyst-stage embryo transfer in the first treatment cycle. | 27.3 | 0 | 2 |
| Mature oocyte cryopreservation: a guideline | 27.3 | 0 | 2 |
| Neonatal outcome and birth defects in 6623 singletons born following minimal ovarian stimulation and vitrified versus fresh single embryo transfer | 27.3 | 0 | 2 |
| Lapse in embryo transfer training does not negatively affect clinical pregnancy rates for reproductive endocrinology and infertility fellows | 27.3 | 0 | 2 |
| Recommendations for development of an emergency plan for in vitro fertilization programs: a committee opinion | 27.3 | 0 | 2 |
| Recommendations for development of an emergency plan for in vitro fertilization programs: a committee opinion | 27.3 | 0 | 2 |
| Guidelines for development of an emergency plan for in vitro fertilization programs | 27.3 | 0 | 2 |
| Ovarian stimulation and corpus luteum function in human in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Fertility Treatments in the United States: Improving Access and Outcomes | 27.3 | 0 | 2 |
| Preprogrammed, unmonitored ovarian stimulation reduces expense without compromising the outcome of assisted reproduction | 27.3 | 0 | 2 |
| Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression | 27.3 | 0 | 2 |
| Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation | 27.3 | 0 | 2 |
| IVF Treatment and Single Embryo Transfer | 27.3 | 0 | 2 |
| Effect of high-dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles | 27.3 | 0 | 2 |
| A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count | 27.3 | 0 | 2 |
| Lyophilised hMG versus rFSH in women with unexplained infertility undergoing a controlled ovarian stimulation with intrauterine insemination: a prospective, randomised study. | 27.3 | 0 | 2 |
| First live birth following IVF-embryo transfer and use of GnRHa alone for ovarian stimulation | 27.3 | 0 | 2 |
| Refuting a misguided campaign against the goal of single-embryo transfer and singleton birth in assisted reproduction | 27.3 | 0 | 2 |
| An effective alternative to only gonadotrophin for controlled ovarian stimulation in unexplained infertility patients undergoing intra-uterine insemination: a clinical trial | 27.3 | 0 | 2 |
| Comparison of aneuploidy, pregnancy and live birth rates between day 5 and day 6 blastocysts | 27.3 | 0 | 2 |
| Usage of herbal medications in patients undergoing IVF treatment in an Irish infertility treatment unit | 27.3 | 0 | 2 |
| Repetitive oocyte donation: a committee opinion | 27.3 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 27.3 | 0 | 2 |
| Life after unsuccessful IVF treatment in an assisted reproduction unit: a qualitative analysis of gains through loss among Chinese persons in Hong Kong. | 27.3 | 0 | 2 |
| Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. | 27.3 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 27.3 | 0 | 2 |
| Estimation of the Contribution of Assisted and Non-Assisted Reproductive Technology Fertility Treatments to Multiple Births During the Past 30 Years in Japan: 1979–2008 | 27.3 | 0 | 2 |
| Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation | 27.3 | 0 | 2 |
| Perinatal outcomes after assisted reproductive technology treatment in Australia and New Zealand: single versus double embryo transfer. | 27.3 | 0 | 2 |
| Role of semen analysis in subfertile couples | 27.3 | 0 | 2 |
| The relationship between endogenous oestradiol and vitamin D3 metabolites in serum and follicular fluid during ovarian stimulation for in-vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| The effect of smoking on infertility treatment in women undergoing assisted reproduction cycles | 27.3 | 0 | 2 |
| Follicular fluid-induced acrosome reaction distinguishes a subgroup of men with unexplained infertility not identified by semen analysis | 27.3 | 0 | 2 |
| Personal experience with ovarian stimulation in an in vitro fertilization and embryo transfer program | 27.3 | 0 | 2 |
| The serum concentration of estradiol after embryo transfer and the decline from preovulatory levels may influence the success of IVF treatment | 27.3 | 0 | 2 |
| Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility | 27.3 | 0 | 2 |
| LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. | 27.3 | 0 | 2 |
| Effect of ovarian stimulation on plasma lipid and apolipoprotein concentrations in a population of infertile women undergoing IVF/embryo transfer | 27.3 | 0 | 2 |
| IVF with planned single-embryo transfer versus IUI with ovarian stimulation in couples with unexplained subfertility: an economic analysis | 27.3 | 0 | 2 |
| Ovarian stimulation for in vitro fertilization and embryo transfer, human menopausal gonadotropin versus pure human follicle stimulating hormone: a randomized prospective study. | 27.3 | 0 | 2 |
| Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study | 27.3 | 0 | 2 |
| Comparison of clinical outcome of mild-stimulation and conventional ovarian stimulation in in vitro fertilization-embryo transfer (IVF-ET) | 27.3 | 0 | 2 |
| Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation | 27.3 | 0 | 2 |
| Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility | 27.3 | 0 | 2 |
| Perspective on in vitro fertilization and embryo transfer. Stimulus for biomedical research in reproductive medicine | 27.3 | 0 | 2 |
| Evidence-based medicine and the role of the private sector in assisted reproduction: a response to Dr Fishel’s commentary ‘Evidenced-based medicine and the role of the National Health Service in assisted reproduction’ | 27.3 | 0 | 2 |
| Paternal body mass index is associated with decreased blastocyst development and reduced live birth rates following assisted reproductive technology | 27.3 | 0 | 2 |
| Risk-sharing or refund programs in assisted reproduction: a committee opinion | 27.3 | 0 | 2 |
| Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility. | 27.3 | 0 | 2 |
| Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial | 27.3 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome. | 27.3 | 0 | 2 |
| Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment | 27.3 | 0 | 2 |
| Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial | 27.3 | 0 | 2 |
| Society for Assisted Reproductive Technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for Assisted Reproductive Technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Human immunodeficiency virus and infertility treatment | 27.3 | 0 | 2 |
| Society for assisted reproductive technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Society for assisted reproductive technology position statement on donor suitability of recipients of smallpox vaccine (vaccinia virus). | 27.3 | 0 | 2 |
| Human immunodeficiency virus and infertility treatment | 27.3 | 0 | 2 |
| Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation | 27.3 | 0 | 2 |
| A Study of Controlled Ovarian Stimulation with Clomiphene Citrate or Letrozole in Combination with Gonadotropins and IUI in Unexplained Infertility | 27.3 | 0 | 2 |
| Response to 'Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?'. | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Public policy aspects of assisted reproduction. Vth World Congress, IVF and embryo transfer | 27.3 | 0 | 2 |
| Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin | 27.3 | 0 | 2 |
| Prognostic indicators of assisted reproduction technology outcomes of cycles with ultralow serum antimüllerian hormone: a multivariate analysis of over 5,000 autologous cycles from the Society for Assisted Reproductive Technology Clinic Outcome Repo | 27.3 | 0 | 2 |
| Ovarian stimulation, egg aspiration, in vitro fertilization and embryo transfer in the baboon (Papio anubis): a pilot project at the Institute of Primate Research, Nairobi, Kenya | 27.3 | 0 | 2 |
| Trends and factors associated with the Day 5 embryo transfer, assisted reproductive technology surveillance, USA, 2001-2009. | 27.3 | 0 | 2 |
| The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium. | 27.3 | 0 | 2 |
| Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial | 27.3 | 0 | 2 |
| Evolution of a reproductive endocrinologist: the Society for Reproductive Endocrinology and Infertility fellows retreat and preliminary results of manpower survey | 27.3 | 0 | 2 |
| Embryo transfer practices in the United States: a survey of clinics registered with the Society for Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Posthumous assisted reproduction: a survey of attitudes of couples seeking fertility treatment and the degree of agreement between intimate partners | 27.3 | 0 | 2 |
| Viral infections among couples for assisted reproduction in a fertility clinic in Nigeria. | 27.3 | 0 | 2 |
| Factors associated with dizygotic twinning after IVF treatment with double embryo transfer | 27.3 | 0 | 2 |
| Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? | 27.3 | 0 | 2 |
| Treatment period and medical care costs to achieve the first live birth by assisted reproductive technology are lower in the single embryo transfer period than in the double embryo transfer period: a retrospective analysis of women younger than 40 y | 27.3 | 0 | 2 |
| The significance of antral follicle count in controlled ovarian stimulation and intrauterine insemination | 27.3 | 0 | 2 |
| An analysis of the impact of embryo transfer difficulty on live birth rates, using a standardised grading system | 27.3 | 0 | 2 |
| No increase in autism-associated genetic events in children conceived by assisted reproduction | 27.3 | 0 | 2 |
| Not all twins are monozygotic after elective single embryo transfer: analysis of 32,600 elective single embryo transfer cycles as reported to the Society for Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Intrauterine insemination with ovarian stimulation versus expectant management for unexplained infertility (TUI): a pragmatic, open-label, randomised, controlled, two-centre trial | 27.3 | 0 | 2 |
| Are attachment dimensions associated with infertility-related stress in couples undergoing their first IVF treatment? A study on the individual and cross-partner effect. | 27.3 | 0 | 2 |
| Preconceptional antithyroid peroxidase antibodies, but not thyroid-stimulating hormone, are associated with decreased live birth rates in infertile women | 27.3 | 0 | 2 |
| Assisted reproductive technology (ART) cumulative live birth rates following preimplantation genetic diagnosis for aneuploidy (PGD-A) or morphological assessment of embryos: A cohort analysis. | 27.3 | 0 | 2 |
| Stimulation of endometrium embryo transfer can improve implantation and pregnancy rates for patients undergoing assisted reproductive technology for the first time with a high-grade blastocyst | 27.3 | 0 | 2 |
| Congenital Malformations in Singleton Infants Conceived by Assisted Reproductive Technologies and Singleton Infants by Natural Conception in Tehran, Iran | 27.3 | 0 | 2 |
| Cumulative pregnancy and live birth rates through assisted reproduction in women 44-45 years of age: is there any hope? | 27.3 | 0 | 2 |
| Does ovarian stimulation regimen affect IVF outcome? a two-centre, real-world retrospective study using predominantly cleavage-stage, single embryo transfer | 27.3 | 0 | 2 |
| Association Between Pesticide Residue Intake From Consumption of Fruits and Vegetables and Pregnancy Outcomes Among Women Undergoing Infertility Treatment With Assisted Reproductive Technology | 27.3 | 0 | 2 |
| The Importance of the Periconception Period: Immediate Effects in Cattle Breeding and in Assisted Reproduction Such as Artificial Insemination and Embryo Transfer | 27.3 | 0 | 2 |
| Evaluation of trend in semen analysis for 11 years in subjects attending a fertility clinic in India. | 27.3 | 0 | 2 |
| Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Financial "risk-sharing" or refund programs in assisted reproduction: an Ethics Committee opinion | 27.3 | 0 | 2 |
| The impact of the new Turkish regulation, imposing single embryo transfer after assisted reproduction technology, on neonatal intensive care unit utilization: a single center experience. | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry | 27.3 | 0 | 2 |
| Combined advanced parental age has an additive negative effect on live birth rates-data from 4057 first IVF/ICSI cycles. | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1999 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1998 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| A Focus on Maternal Health Before Assisted Reproduction: Results From a Pilot Survey of Canadian IVF Medical Directors | 27.3 | 0 | 2 |
| Assisted reproductive technology in reproductive medicine - possibilities and limitations | 27.3 | 0 | 2 |
| Reproductive Ethics in Commercial Surrogacy: Decision-Making in IVF Clinics in New Delhi, India | 27.3 | 0 | 2 |
| The use of luteal-phase ovarian stimulation for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment | 27.3 | 0 | 2 |
| Effect of premature serum progesterone rise on embryo transfer outcomes and the role of blastocyst culture and transfer in assisted reproductive technology cycles with premature progesterone rise | 27.3 | 0 | 2 |
| Elevated serum estradiol levels in artificial autologous frozen embryo transfer cycles negatively impact ongoing pregnancy and live birth rates | 27.3 | 0 | 2 |
| New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles | 27.3 | 0 | 2 |
| Do endometriomas grow during ovarian stimulation for assisted reproduction? A three-dimensional volume analysis before and after ovarian stimulation | 27.3 | 0 | 2 |
| Melatonin concentration in follicular fluid is correlated with antral follicle count (AFC) and in vitro fertilization (IVF) outcomes in women undergoing assisted reproductive technology (ART) procedures. | 27.3 | 0 | 2 |
| Patient and cycle characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology outcomes between 2004 and 2013. | 27.3 | 0 | 2 |
| Initial maternal serum human chorionic gonadotropin levels in pregnancies achieved after assisted reproductive technology are higher after preimplantation genetic screening and after frozen embryo transfer: a retrospective cohort | 27.3 | 0 | 2 |
| The psychological impact of mild ovarian stimulation combined with single embryo transfer compared with conventional IVF. | 27.3 | 0 | 2 |
| Cryopreserved embryo transfer: adjacent or non-adjacent to failed fresh long GnRH-agonist protocol IVF cycle | 27.3 | 0 | 2 |
| Uncommon but devastating event: total fertilisation failure following intracytoplasmic sperm injection | 27.3 | 0 | 2 |
| Self-operated endovaginal telemonitoring versus traditional monitoring of ovarian stimulation in assisted reproduction: an RCT | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies: a committee opinion | 27.3 | 0 | 2 |
| Pregnancy rates in donor oocyte cycles compared to similar autologous in vitro fertilization cycles: an analysis of 26,457 fresh cycles from the Society for Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. | 27.3 | 0 | 2 |
| The impact of legally restricted embryo transfer and reimbursement policy on cumulative delivery rate after treatment with assisted reproduction technology | 27.3 | 0 | 2 |
| Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles | 27.3 | 0 | 2 |
| What is the quality of information on social oocyte cryopreservation provided by websites of Society for Assisted Reproductive Technology member fertility clinics? | 27.3 | 0 | 2 |
| Recommendations for gamete and embryo donation: a committee opinion | 27.3 | 0 | 2 |
| Colour Doppler assessment of ascendent uterine artery perfusion in an in-vitro fertilization-embryo transfer programme after pituitary desensitization and ovarian stimulation with human recombinant follicle stimulating hormone | 27.3 | 0 | 2 |
| Predicting ovarian reserve and reproductive outcome using antimüllerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure | 27.3 | 0 | 2 |
| Double embryo transfer gives good pregnancy and live birth rates in poor responders with a modest increase in multiple birth rates: results from an observational study | 27.3 | 0 | 2 |
| Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates | 27.3 | 0 | 2 |
| Randomized comparison of different ovarian stimulation regimens for assisted reproductive technology in baboons (Papio anubis). | 27.3 | 0 | 2 |
| 2008 Guidelines for gamete and embryo donation: a Practice Committee report | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI). | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion | 27.3 | 0 | 2 |
| Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment | 27.3 | 0 | 2 |
| Guidelines for development of an emergency plan for in vitro fertilization programs | 27.3 | 0 | 2 |
| Predictors of ongoing pregnancy after single-embryo transfer following mild ovarian stimulation for IVF. | 27.3 | 0 | 2 |
| New alternative to infertility treatment for women without ovarian stimulation. | 27.3 | 0 | 2 |
| Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation | 27.3 | 0 | 2 |
| Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment | 27.3 | 0 | 2 |
| Estimation of the contribution of non-assisted reproductive technology ovulation stimulation fertility treatments to US singleton and multiple births | 27.3 | 0 | 2 |
| Assisted reproduction technique outcomes for fresh versus deferred cryopreserved day-2 embryo transfer: a retrospective matched cohort study | 27.3 | 0 | 2 |
| Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group | 27.3 | 0 | 2 |
| Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study | 27.3 | 0 | 2 |
| Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles | 27.3 | 0 | 2 |
| Endocrinology: Endogenous plasma growth hormone and the occurrence of pregnancies in patients undergoing in-vitro fertilization and embryo transfer with ovarian stimulation | 27.3 | 0 | 2 |
| Selection of ovarian stimulation protocol is related to IVF treatment outcome in women 35 years of age and older | 27.3 | 0 | 2 |
| Outcome of donor versus husband insemination in couples with unexplained infertility treated by in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Bilateral salpingectomy does not compromise ovarian stimulation in an in-vitro fertilization/embryo transfer programme | 27.3 | 0 | 2 |
| Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction | 27.3 | 0 | 2 |
| Birthweight of singletons after assisted reproduction is higher after single- than after double-embryo transfer | 27.3 | 0 | 2 |
| Infertility treatment strategy involving combined freeze-all embryos and single vitrified-warmed embryo transfer during hormonal replacement cycle for in vitro fertilization of women with hypogonadotropic hypogonadism | 27.3 | 0 | 2 |
| Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013. | 27.3 | 0 | 2 |
| On the Origins of the Semen Analysis: A Close Relationship with the History of the Reproductive Medicine | 27.3 | 0 | 2 |
| Role of FSHR rs6165 and ESR2 rs4986938 polymorphisms in ovarian stimulation of Iranian women who underwent assisted reproduction treatment | 27.3 | 0 | 2 |
| Assisted reproductive technology : strategies of elective single embryo transfer | 27.3 | 0 | 2 |
| Do trained reproductive endocrinologists perform better than their trainees? Comparing clinical pregnancy rates and live birth rates after transfer of single fresh blastocysts. | 27.3 | 0 | 2 |
| Comparison of embryo transfer strategies and assisted reproduction outcome in Slovenian and cross-border patients | 27.3 | 0 | 2 |
| CLINICAL ASSISTED REPRODUCTION: Comparison of Recombinant and Urinary Follicle-Stimulating Hormone Preparations in Short-Term Gonadotropin Releasing Hormone Agonist Protocol for In Vitro Fertilization-Embryo Transfer | 27.3 | 0 | 2 |
| Bioethical dilemmas of assisted reproduction in the opinions of Polish women in infertility treatment: a research report | 27.3 | 0 | 2 |
| Costs of medically assisted reproduction treatment at specialized fertility clinics in the Danish public health care system: results from a 5-year follow-up cohort study | 27.3 | 0 | 2 |
| Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers | 27.3 | 0 | 2 |
| 1995 assisted reproductive technology success rates: national summary and fertility clinic report. | 27.3 | 0 | 2 |
| 2006 Guidelines for Gamete and Embryo Donation | 27.3 | 0 | 2 |
| Elements to be considered in obtaining informed consent for ART. | 27.3 | 0 | 2 |
| Optimum number of oocytes for a successful first IVF treatment cycle | 27.3 | 0 | 2 |
| Use of serum inhibin B levels at the start of ovarian stimulation and at oocyte pickup in the prediction of assisted reproduction treatment outcome | 27.3 | 0 | 2 |
| Use of fetal oocytes in assisted reproduction | 27.3 | 0 | 2 |
| Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction | 27.3 | 0 | 2 |
| Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI and embryo transfer (ET). | 27.3 | 0 | 2 |
| Changes induced in serum protein profiles by ovarian stimulation during in-vitro fertilization--embryo transfer treatment: a comparison between conception and non-conception cycles | 27.3 | 0 | 2 |
| Further observations on serial serum immunoreactive inhibin levels in the luteal phase and early gestation after ovarian stimulation for in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Comparison of four different ovarian stimulation protocols in an in vitro fertilisation & embryo transfer programme | 27.3 | 0 | 2 |
| Treatment of patients with unexplained infertility: gamete intrafallopian transfer (GIFT) versus tubal embryo transfer (TET) | 27.3 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 27.3 | 0 | 2 |
| Low negative affect prior to treatment is associated with a decreased chance of live birth from a first IVF cycle | 27.3 | 0 | 2 |
| Expectations for success in fertility treatment involving assisted reproduction | 27.3 | 0 | 2 |
| Reproductive medicine in transition: new developments in embryo transfer | 27.3 | 0 | 2 |
| Efficacy of intrauterine inseminations as a training modality for performing embryo transfer in reproductive endocrinology and infertility fellowship programs. | 27.3 | 0 | 2 |
| Intrauterine administration of hCG-activated autologous human peripheral blood mononuclear cells (PBMC) promotes live birth rates in frozen/thawed embryo transfer cycles of patients with repeated implantation failure | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| Is there a need for recombinant human luteinizing hormone (lutropin alfa) supplementation in ovarian stimulation for assisted reproduction? | 27.3 | 0 | 2 |
| Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An ana | 27.3 | 0 | 2 |
| AIDA for reproductive medicine and the fertility clinic | 27.3 | 0 | 2 |
| Subnormal sperm parameters in conventional semen analysis are associated with discrepancies between fertilization and pregnancy rates in in-vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| Selective early elimination of luteal support in assisted reproduction cycles using a gonadotropin-releasing hormone agonist during ovarian stimulation | 27.3 | 0 | 2 |
| Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer | 27.3 | 0 | 2 |
| Live birth rates in the first complete IVF cycle among 20 687 women using a freeze-all strategy | 27.3 | 0 | 2 |
| Beyond the American Society for Reproductive Medicine transfer guidelines: how many cleavage-stage embryos are safe to transfer in women ≥43 years old? | 27.3 | 0 | 2 |
| Economic implications of the Society for Assisted Reproductive Technology embryo transfer guidelines: healthcare dollars saved by reducing iatrogenic triplets | 27.3 | 0 | 2 |
| Reply: Models for predicting live birth before a first IVF cycle | 27.3 | 0 | 2 |
| Estrous cycle staging before mating led to increased efficiency in the production of pseudopregnant recipients without negatively affecting embryo transfer in mice | 27.3 | 0 | 2 |
| Anti-Müllerian hormone levels after laparoscopic cystectomy for endometriomas as a possible predictor for pregnancy in infertility treatments | 27.3 | 0 | 2 |
| AIUM practice guideline for ultrasonography in reproductive medicine | 27.3 | 0 | 2 |
| 'Elective single embryo transfer (eSET) reduces pregnancy rates and should only be used in exceptional circumstances': AGAINST: SET maintains live birth rates and provides unique advantages | 27.3 | 0 | 2 |
| Surveillance of congenital malformations in infants conceived through assisted reproductive technology or other fertility treatments | 27.3 | 0 | 2 |
| Suitable fresh embryo transfer strategy for mild ovarian stimulation with clomiphene citrate | 27.3 | 0 | 2 |
| Endometrial Scratch Injury Induces Higher Pregnancy Rate for Women With Unexplained Infertility Undergoing IUI With Ovarian Stimulation: A Randomized Controlled Trial | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: a committee opinion | 27.3 | 0 | 2 |
| Comparison of the effect of immediate versus delayed transfer following a stimulated IVF cycle on the ongoing pregnancy rate of frozen-thawed embryo transfer cycles: a study protocol for a randomised controlled trial. | 27.3 | 0 | 2 |
| Infertility-related stress, anxiety and ovarian stimulation: can couples be reassured about the effects of psychological factors on biological responses to assisted reproductive technology? | 27.3 | 0 | 2 |
| Trust women to choose: a response to John a Robertson's 'Egg freezing and Egg banking: empowerment and alienation in assisted reproduction'. | 27.3 | 0 | 2 |
| Cumulative live birth rates according to the number of oocytes retrieved after the first ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a multicenter multinational analysis including ∼15,000 women | 27.3 | 0 | 2 |
| Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation | 27.3 | 0 | 2 |
| In-vitro fertilization (IVF), embryo transfer (ET) and assisted reproduction in the State of Israel | 27.3 | 0 | 2 |
| Reply: Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer | 27.3 | 0 | 2 |
| Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer: where is the evidence? | 27.3 | 0 | 2 |
| Abstracts for 2018 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Preimplantation genetic testing for aneuploidy is cost-effective, shortens treatment time, and reduces the risk of failed embryo transfer and clinical miscarriage | 27.3 | 0 | 2 |
| Application of seminal plasma to female genital tract prior to embryo transfer in assisted reproductive technology cycles (IVF, ICSI and frozen embryo transfer) | 27.3 | 0 | 2 |
| Sharing of human leukocyte antigens in couples with unexplained infertility affects the success of in vitro fertilization and tubal embryo transfer | 27.3 | 0 | 2 |
| Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? | 27.3 | 0 | 2 |
| Misconduct in third-party assisted reproduction: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Observational retrospective study of US national utilisation patterns and live birth rates for various ovarian stimulation protocols for in vitro fertilisation | 27.3 | 0 | 2 |
| THE OPTIMAL INTERVAL OF TIME FROM OPERATIVE HYSTEROSCOPY TO EMBRYO TRANSFER IN AN IVF CYCLE | 27.3 | 0 | 2 |
| Disclosure of sex when incidentally revealed as part of preimplantation genetic testing (PGT): an Ethics Committee opinion | 27.3 | 0 | 2 |
| Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Gender reassignment and assisted reproduction: An ethical analysis. Bristol Centre for Reproductive Medicine Ethics Advisory Committee | 27.3 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction. The Ethics Committee of the American Society for Reproductive Medicine | 27.3 | 0 | 2 |
| Is tissue factor pathway inhibitor a marker of procoagulable status in healthy infertile women undergoing ovarian stimulation for assisted reproduction? | 27.3 | 0 | 2 |
| The effectiveness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study**Presented in part at the 51st Annual Meeting of the American Society for Reproductive Medicine, Seattle, Wa | 27.3 | 0 | 2 |
| Mid-Luteal 17-OH Progesterone Levels in 614 Women Undergoing IVF-Treatment and Fresh Embryo Transfer—Daytime Variation and Impact on Live Birth Rates | 27.3 | 0 | 2 |
| Cumulative pregnancy and live birth rates in women with antiphospholipid antibodies undergoing assisted reproduction | 27.3 | 0 | 2 |
| Unexplained Infertility and the Possibilities of Management with In Vitro Fertilization and Embyro Transfer | 27.3 | 0 | 2 |
| Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review | 27.3 | 0 | 2 |
| Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis | 27.3 | 0 | 2 |
| Large for gestational age and macrosomia in singletons born after frozen/thawed embryo transfer (FET) in assisted reproductive technology (ART) | 27.3 | 0 | 2 |
| Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer | 27.3 | 0 | 2 |
| Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle | 27.3 | 0 | 2 |
| Single Human Embryo Transfer in Assisted Reproduction Programs | 27.3 | 0 | 2 |
| Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1) | 27.3 | 0 | 2 |
| Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2) | 27.3 | 0 | 2 |
| Health in Childhood Following Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol | 27.3 | 0 | 2 |
| GnRH Agonist at Embryo Transfer: IVF Outcomes | 27.3 | 0 | 2 |
| Clinical Cohort Study on the Endocrinology and Vaginal Microbiome of the Luteal Phase in Assisted Reproduction | 27.3 | 0 | 2 |
| Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression | 27.3 | 0 | 2 |
| Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART) | 27.3 | 0 | 2 |
| Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle? | 27.3 | 0 | 2 |
| Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles | 27.3 | 0 | 2 |
| Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol | 27.3 | 0 | 2 |
| Abstracts for 2017 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 27.3 | 0 | 2 |
| Neonatal outcomes following different ovarian stimulation protocols in fresh single embryo transfer | 27.3 | 0 | 2 |
| Safety data for the use of nasal human menopausal gonadotropins: a potential novel approach for fertility treatment | 27.3 | 0 | 2 |
| A cost-effectiveness analysis of preimplantation genetic testing for aneuploidy (PGT-A) for up to three complete assisted reproductive technology cycles in women of advanced maternal age | 27.3 | 0 | 2 |
| Risk of Preeclampsia in Pregnancies After Assisted Reproductive Technology and Ovarian Stimulation | 27.3 | 0 | 2 |
| Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment | 27.3 | 0 | 2 |
| Efficacy of Hypnosis During Embryo Transfer Procedure on Clinical Pregnancy Rate for Patients Undergoing Assisted Reproductive Technology IVF or ICSI | 27.3 | 0 | 2 |
| Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2 | 27.3 | 0 | 2 |
| Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1 | 27.3 | 0 | 2 |
| Letrozole in Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Biomarkers of Ovarian Reserve and Correlation With IVF Treatments | 27.3 | 0 | 2 |
| A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment | 27.3 | 0 | 2 |
| Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program | 27.3 | 0 | 2 |
| A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment | 27.3 | 0 | 2 |
| Electro-acupuncture and Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Bed Rest or no Bed Rest? | 27.3 | 0 | 2 |
| Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization | 27.3 | 0 | 2 |
| The Effect of Selective Serotonin Reuptake Inhibitor (SSRI) Treatment on Affective Symptoms and Fertility Treatment Outcome in Women Undergoing in Vitro Fertilization (IVF) | 27.3 | 0 | 2 |
| CONSORT Randomized Controlled Trial in Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Egg Freezing Pilot Study | 27.3 | 0 | 2 |
| MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer | 27.3 | 0 | 2 |
| Temporally Splitting Ovarian Stimulation and Embryo Transfer | 27.3 | 0 | 2 |
| Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility | 27.3 | 0 | 2 |
| EmbryoGlue as an Embryo Transfer Medium | 27.3 | 0 | 2 |
| Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women | 27.3 | 0 | 2 |
| The Accuracy of Endometrial Ultrasound to Predict Implantation | 27.3 | 0 | 2 |
| Uterine Flushing With Human Chorionic Gonadotrophin and Unexplained Infertility | 27.3 | 0 | 2 |
| Influence of Post-thaw Embryo Culture Interval on Assisted Reproduction Success Rates | 27.3 | 0 | 2 |
| DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore | 27.3 | 0 | 2 |
| Urinary Versus Recombinant Gonadotropins for Ovarian Stimulation in Women Undergoing Treatment with Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: a multi-center randomized controlled trial. | 27.3 | 0 | 2 |
| Endometrial Scratch Injury in Women With Unexplained Infertility Undergoing IUI | 27.3 | 0 | 2 |
| HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients | 27.3 | 0 | 2 |
| Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment | 27.3 | 0 | 2 |
| Effect of Local Injury on Implantation | 27.3 | 0 | 2 |
| Immediate Versus Delayed FET Following a Stimulated IVF Cycle | 27.3 | 0 | 2 |
| Pharmacogenetic Algorithm for Individualized Controlled Ovarian Stimulation | 27.3 | 0 | 2 |
| To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment | 27.3 | 0 | 2 |
| Newborns From Patients Treated With ART (Assisted Reproductive Technology) | 27.3 | 0 | 2 |
| The Use of an Online Learning and Consent Platform in Infertility Treatment | 27.3 | 0 | 2 |
| Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women | 27.3 | 0 | 2 |
| NATural Ovarian Stimulation | 27.3 | 0 | 2 |
| Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles | 27.3 | 0 | 2 |
| Study Comparing Outcomes Between Conventional IVF and a "Freeze-all"-Strategy in Assisted Reproductive Technology | 27.3 | 0 | 2 |
| A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation | 27.3 | 0 | 2 |
| Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients | 27.3 | 0 | 2 |
| HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients | 27.3 | 0 | 2 |
| In vitro fertilization-embryo transfer (IVF-ET) in the United States: 1990 results from the IVF-ET Registry. Medical Research International. Society for Assisted Reproductive Technology (SART), The American Fertility Society | 27.3 | 0 | 2 |
| A randomized trial between GIFT and ovarian stimulation for the treatment of unexplained infertility and failed artificial insemination by donor | 27.3 | 0 | 2 |
| The performance of primary and secondary unexplained infertility in an in vitro fertilization-embryo transfer program | 27.3 | 0 | 2 |
| In vitro fertilization-embryo transfer (IVF-ET) in the United States: 1989 results from the IVF-ET Registry. Medical Research International, Society for Assisted Reproductive Technology, The American Fertility Society | 27.3 | 0 | 2 |
| Evaluation of the Hamilton-Thorn 2030 motility analyser for routine semen analysis in an infertility clinic | 27.3 | 0 | 2 |
| In vitro fertilization-embryo transfer in the United States: 1988 results from the IVF-ET Registry. Medical Research International. Society for Assisted Reproductive Technology. American Fertility Society | 27.3 | 0 | 2 |
| Outcome of in-vitro fertilization and embryo transfer after different regimens of ovarian stimulation | 27.3 | 0 | 2 |
| Differential indications for surgical technics in reproductive medicine--microsurgery, in vitro fertilization and embryo transfer, gamete intrafallopian transfer and tubal embryo transfer | 27.3 | 0 | 2 |
| Clomiphene-HMG ovarian stimulation in human in vitro fertilization and embryo transfer | 27.3 | 0 | 2 |
| In vitro fertilization and other assisted reproduction. Vth World Congress on In Vitro Fertilization and Embryo Transfer. Norfolk, Virginia, April 5-10, 1987. Proceedings | 27.3 | 0 | 2 |
| An analysis of the LH profile in relation to ovarian stimulation regimes and embryo transfer rates in an in vitro fertilisation programme | 27.3 | 0 | 2 |
| The effect of periovarian adhesions on follicular development in patients undergoing ovarian stimulation for in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Morphometric characteristics of endometrial biopsies after different types of ovarian stimulation for infertility treatment | 27.3 | 0 | 2 |
| Gamete intra-Fallopian transfer or in-vitro fertilization after failed ovarian stimulation and intrauterine insemination in unexplained infertility? | 27.3 | 0 | 2 |
| Sonographically monitored ovarian stimulation for assisted reproduction: a prospective, blind study | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States and Canada: 1994 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| In vitro fertilization/embryo transfer in unexplained infertility and minimal peritoneal endometriosis | 27.3 | 0 | 2 |
| Fallopian Tube Sperm Perf usion Has No Advantage over Intra-uterine Insemination when Used in Combination with Ovarian Stimulation for the Treatment of Unexplained Infertility | 27.3 | 0 | 2 |
| Methodology of human embryo transfer following assisted reproduction | 27.3 | 0 | 2 |
| Immunity to zona pellucida in women with low response to ovarian stimulation, in unexplained infertility and after multiple IVF attempts | 27.3 | 0 | 2 |
| A prospective randomized crossover comparison of zygote intrafallopian transfer and in vitro fertilization-embryo transfer in unexplained infertility | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States and Canada: 1993 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| The results of in vitro fertilization-embryo transfer in couples with unexplained infertility failing to conceive with superovulation and intrauterine insemination | 27.3 | 0 | 2 |
| Luteinizing hormone (LH) surge in patients using buserelin spray during ovarian stimulation for assisted reproduction | 27.3 | 0 | 2 |
| Reproductive medicine and assisted reproduction--present status and perspectives in the Czech Republic | 27.3 | 0 | 2 |
| Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1997 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| A comparison of early gestational age markers in viable twin pregnancies resulting from in vitro fertilization-embryo transfer versus spontaneous conception with ovarian stimulation | 27.3 | 0 | 2 |
| A rational basis for antiphospholipid antibody testing and selective immunotherapy in assisted reproduction: a rebuttal to the American Society for Reproductive Medicine Practice opinion. American Society for Reproductive Immunology Antiphospholipid | 27.3 | 0 | 2 |
| Relationship between semen cultures, leukospermia, and semen analysis in men undergoing fertility evaluation | 27.3 | 0 | 2 |
| The influence of infertility treatment and assisted reproduction techniques on multiple pregnancy rates | 27.3 | 0 | 2 |
| Recombinant versus urinary FSH for ovarian stimulation in assisted reproduction | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI) | 27.3 | 0 | 2 |
| Embryo transfer: a critical step in assisted reproduction | 27.3 | 0 | 2 |
| A case of forearm amputation after ovarian stimulation for in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation | 27.3 | 0 | 2 |
| Assisted Reproductive Technology in the United States and Canada: 1995 Results Generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Leukaemia inhibitory factor (LIF) gene mutations in women with unexplained infertility and recurrent failure of implantation after IVF and embryo transfer | 27.3 | 0 | 2 |
| Transfer of early-cleaved embryos increases implantation rate in patients undergoing ovarian stimulation and ICSI-embryo transfer | 27.3 | 0 | 2 |
| A real-life prospective health economic study of elective single embryo transfer versus two-embryo transfer in first IVF/ICSI cycles | 27.3 | 0 | 2 |
| The Impact of Lifestyle on Sperm Telomere Length and Telomerase Activity in Men Undergoing IVF Treatments | 27.3 | 0 | 2 |
| Assisted reproductive technology in the United States: 1996 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry | 27.3 | 0 | 2 |
| Infertility treatment and informed consent: current practices of reproductive endocrinologists | 27.3 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction | 27.3 | 0 | 2 |
| Predictive value of the results of a first IVF cycle | 27.3 | 0 | 2 |
| Impact of patients' choice for single embryo transfer of a top quality embryo versus double embryo transfer in the first IVF/ICSI cycle | 27.3 | 0 | 2 |
| Follitropin-alfa for ovarian stimulation during assisted reproduction treatment: a national collaborative study | 27.3 | 0 | 2 |
| Effectiveness and treatment for unexplained infertility | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A Committee opinion | 27.3 | 0 | 2 |
| Ovarian tissue and oocyte cryopreservation | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Preimplantation genetic diagnosis | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 27.3 | 0 | 2 |
| [Towards a single embryo transfer: predictive value of uterine and embryological parameters in assisted reproduction outcome] | 27.3 | 0 | 2 |
| Cervical dilatation with hygroscopic rods prior to ovarian stimulation facilitates embryo transfer | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Elective single embryo transfer in assisted reproduction | 27.3 | 0 | 2 |
| Graduated Embryo Score and soluble human leukocyte antigen-G expression improve assisted reproductive technology outcomes and suggest a basis for elective single-embryo transfer | 27.3 | 0 | 2 |
| Health of children born after the infertility treatment with Assisted Reproduction Technology | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Extended encounters with midwives at the first IVF cycle: a controlled trial | 27.3 | 0 | 2 |
| Removal of cervical mucus prior to embryo transfer improves pregnancy rates in women undergoing assisted reproduction | 27.3 | 0 | 2 |
| First IVF treatment--short-term impact on psychological well-being and the marital relationship | 27.3 | 0 | 2 |
| Assisted reproductive technology practice patterns and the impact of embryo transfer guidelines in the United States | 27.3 | 0 | 2 |
| The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society for Assisted Reproductive Technology/American Society for Reproductive Medicine recommendation | 27.3 | 0 | 2 |
| Guidelines for advertising by ART programs | 27.3 | 0 | 2 |
| Guidelines on the number of embryos transferred | 27.3 | 0 | 2 |
| Guidelines for advertising by ART programs | 27.3 | 0 | 2 |
| Revised minimum standards for practices offering assisted reproductive technologies | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Round spermatid nucleus injection (ROSNI) | 27.3 | 0 | 2 |
| Blastocyst production and transfer in clinical assisted reproduction | 27.3 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction | 27.3 | 0 | 2 |
| Embryo splitting for infertility treatment | 27.3 | 0 | 2 |
| Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples | 27.3 | 0 | 2 |
| Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916) | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 27.3 | 0 | 2 |
| Would legislation imposing single embryo transfer be a feasible way to reduce the rate of multiple pregnancies after IVF treatment? | 27.3 | 0 | 2 |
| In vitro fertilization laboratory. Clinical features of assisted reproduction techniques. Male infertility treatment in a reproduction medicine centre | 27.3 | 0 | 2 |
| Assisted reproductive technology has been detrimental to academic reproductive endocrinology and infertility | 27.3 | 0 | 2 |
| Assisted reproductive technology has been detrimental to academic reproductive endocrinology and infertility: depth of the problem and possible solutions | 27.3 | 0 | 2 |
| Elective single embryo transfer versus double embryo transfer in assisted reproduction | 27.3 | 0 | 2 |
| Single embryo transfer in IVF treatment | 27.3 | 0 | 2 |
| Recombinant gonadotrophins in reproductive medicine: gold standard for ovarian stimulation therapy in the 21st century | 27.3 | 0 | 2 |
| Effect of embryo transfer number on singleton and twin implantation pregnancy outcomes after assisted reproductive technology | 27.3 | 0 | 2 |
| Variability of endometrial glandular opening count in infertile patients prior to first IVF treatment | 27.3 | 0 | 2 |
| Response by the leadership of the Society of Assisted Reproductive Technology (SART) to the article “Assisted Reproduction and Choices in the Biotech Age” | 27.3 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 27.3 | 0 | 2 |
| Genetic considerations related to intracytoplasmic sperm injection (ICSI) | 27.3 | 0 | 2 |
| The role of assisted hatching in in vitro fertilization: a review of the literature. A Committee opinion | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Ovarian tissue and oocyte cryopreservation | 27.3 | 0 | 2 |
| Revised guidelines for human embryology and andrology laboratories | 27.3 | 0 | 2 |
| An observational study of assisted reproductive technology outcomes in new European Union member states: an overview of protocols used for ovarian stimulation | 27.3 | 0 | 2 |
| Re: Paternal Body Mass Index is Associated With Decreased Blastocyst Development and Reduced Live Birth Rates Following Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Acupuncture intervention combined with assisted reproductive technology: its different effects at different time points during the in vitro fertilization-embryo transfer course | 27.3 | 0 | 2 |
| Personality and intrapersonal and interpersonal functioning of women starting their first IVF treatment | 27.3 | 0 | 2 |
| Effect of the new legislation and single-embryo transfer policy in Turkey on assisted reproduction outcomes: preliminary results | 27.3 | 0 | 2 |
| Racial and ethnic disparities in assisted reproductive technology pregnancy and live birth rates within body mass index categories | 27.3 | 0 | 2 |
| Committee opinion: role of tubal surgery in the era of assisted reproductive technology | 27.3 | 0 | 2 |
| Practice patterns and outcomes with the use of single embryo transfer in the United States | 27.3 | 0 | 2 |
| Recommendations for practices utilizing gestational carriers: an ASRM Practice Committee guideline | 27.3 | 0 | 2 |
| Prediction of ovarian reserve, poor response and pregnancy outcome based on basal antral follicle count and age in patients undergoing in vitro fertilization-embryo transfer | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: a committee opinion | 27.3 | 0 | 2 |
| Reproductive endocrinology: Infertility treatment in PCOS--is metformin in from the cold? | 27.3 | 0 | 2 |
| Results after assisted reproduction at a public fertility clinic | 27.3 | 0 | 2 |
| Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted reproductive technology: a retrospective study with 2,555 fresh embryo transfers | 27.3 | 0 | 2 |
| Position statement on West Nile virus: a committee opinion | 27.3 | 0 | 2 |
| Correct coding for laboratory procedures during assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Recombinant FSH versus clomiphene citrate for ovarian stimulation in couples with unexplained infertility and male subfertility undergoing intrauterine insemination: a randomized trial | 27.3 | 0 | 2 |
| Guidelines on number of embryos transferred | 27.3 | 0 | 2 |
| Strategies for hormonal ovarian stimulation in IVF, based on materials of the centre for assisted reproduction "varna" | 27.3 | 0 | 2 |
| Effect of different embryo transfer strategies on the outcome of assisted reproduction | 27.3 | 0 | 2 |
| Re: "Estimation of the contribution of non-assisted reproductive technology ovulation stimulation fertility treatments to US singleton and multiple births" | 27.3 | 0 | 2 |
| Criteria for number of embryos to transfer: a committee opinion | 27.3 | 0 | 2 |
| Uterine contractile activity at Embryo Transfer – as a new pharmacotherapeutic target in assisted reproduction | 27.3 | 0 | 2 |
| AIUM Practice Guideline for the Performance of a Focused Reproductive Endocrinology and Infertility Scan | 27.3 | 0 | 2 |
| Re: Fruit and Vegetable Intake and Their Pesticide Residues in Relation to Semen Quality among Men from a Fertility Clinic | 27.3 | 0 | 2 |
| Use of reproductive technology for sex selection for nonmedical reasons | 27.3 | 0 | 2 |
| [Assisted Reproductive Technology in Female Transplant Recipients: Experience of a Reproductive Medicine Unit and Literature Review] | 27.3 | 0 | 2 |
| Role of baseline antral follicle count and anti-Mullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers | 27.3 | 0 | 2 |
| Corrigendum to 'Hysteroscopy prior to a first IVF treatment cycle: the need for well-performed RCT' [Reproductive BioMedicine Online 29 (2014) 142-142] | 27.3 | 0 | 2 |
| Successful pregnancy following assisted reproduction and transmyometrial embryo transfer in a patient with anatomical distortion of the cervical canal | 27.3 | 0 | 2 |
| Hysteroscopy prior to a first IVF treatment cycle: the need for well-performed RCT | 27.3 | 0 | 2 |
| Response: Hysteroscopy prior to a first IVF treatment cycle: the need for well-performed RCT | 27.3 | 0 | 2 |
| Validity for assisted hatching on pregnancy rate in assisted reproductive technology: Analysis based on results of Japan Assisted Reproductive Technology Registry System 2010 | 27.3 | 0 | 2 |
| Is gonadotropin ovarian stimulation for unexplained infertility any longer warranted? | 27.3 | 0 | 2 |
| Effectiveness of mild ovarian stimulation versus GnRH agonist protocol in women undergoing assisted reproductive technology: a meta-analysis | 27.3 | 0 | 2 |
| Midluteal Progesterone: A Marker of Treatment Outcomes in Couples With Unexplained Infertility | 27.3 | 0 | 2 |
| Pharmacogenetic algorithm for individualized controlled ovarian stimulation in assisted reproductive technology cycles | 27.3 | 0 | 2 |
| Models for predicting live birth before a first IVF cycle | 27.3 | 0 | 2 |
| Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients | 27.3 | 0 | 2 |
| Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF: a guideline | 27.3 | 0 | 2 |
| Endometriosis does not affect live birth rates of patients submitted to assisted reproduction techniques: analysis of the Latin American Network Registry database from 1995 to 2011 | 27.3 | 0 | 2 |
| Preimplantation genetic testing in assisted reproductive technology | 27.3 | 0 | 2 |
| ASRM standard embryo transfer protocol template: a committee opinion | 27.3 | 0 | 2 |
| Compassionate transfer: patient requests for embryo transfer for nonreproductive purposes | 27.3 | 0 | 2 |
| Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion | 27.3 | 0 | 2 |
| Timing of frozen-thawed embryo transfer after controlled ovarian stimulation in a non-elective freeze-all policy | 27.3 | 0 | 2 |
| Current Preventive Strategies for Preovulatory Progesterone Elevation During Ovarian Stimulation for In Vitro Fertilization | 27.3 | 0 | 2 |
| Reporting assisted reproductive technology success rates on Australian and New Zealand fertility clinic websites | 27.3 | 0 | 2 |
| The effect of fresh IVF cycle characteristics on frozen embryo transfer (FET) outcomes | 27.3 | 0 | 2 |
| Evidence-based treatments for couples with unexplained infertility: a guideline | 27.3 | 0 | 2 |
| Predictors of twin pregnancy after ovarian stimulation and intrauterine insemination in women with unexplained infertility | 27.3 | 0 | 2 |
| Minimum standards for practices offering assisted reproductive technologies: a committee opinion | 27.3 | 0 | 2 |
| Preimplantation genetic testing in assisted reproduction technology | 27.3 | 0 | 2 |
| Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study | 27.3 | 0 | 2 |
| Single and double embryo transfer provide similar live birth rates in frozen cycles | 27.3 | 0 | 2 |
| Assisted Reproductive Technology and the Reproductive Endocrinology and Infertility Specialist in the U.S. Military | 27.3 | 0 | 2 |
| High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology | 27.3 | 0 | 2 |
| Re: Assisted Reproductive Technology Outcomes in Female-to-Male Transgender Patients Compared with Cisgender Patients: A New Frontier in Reproductive Medicine | 27.3 | 0 | 2 |
| Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial | 27.3 | 0 | 2 |
| Herbal fertility treatments used in North America from colonial times to 1900, and their potential for improving the success rate of assisted reproductive technology | 27.3 | 0 | 2 |
| Elective Single Embryo Transfer in the Setting of Funded In Vitro Fertilization: Two Years' Experience in an Ontario Hospital-Based Fertility Clinic | 27.3 | 0 | 2 |
| Curative effect of assisted reproduction technology by Traditional Chinese Medicine multi-channel interventional therapy on 95 cases of in vitro fertilization and embryo transfer failure | 27.3 | 0 | 2 |
| Ovarian stimulation and assisted reproductive technology outcomes in women transplanted with cryopreserved ovarian tissue: a systematic review | 27.3 | 0 | 2 |
| Assisted reproductive technology outcomes in female-to-male transgender patients compared with cisgender patients: a new frontier in reproductive medicine | 27.3 | 0 | 2 |
| Assessment of Turkey IVF (In Vitro Fertilization) websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 27.3 | 0 | 2 |
| New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology | 27.3 | 0 | 2 |
| Effect of Progestin-primed Ovarian Stimulation Protocol on Outcomes of Aged Infertile Women Who Failed to Get Pregnant in the First IVF/ ICSI Cycle: A Self-controlled Study | 27.3 | 0 | 2 |
| Low serum progesterone the day prior to frozen embryo transfer of euploid embryos is associated with significant reduction in live birth rates | 27.3 | 0 | 2 |
| Low LH Level on the Day of GnRH Agonist Trigger Is Associated With Reduced Ongoing Pregnancy and Live Birth Rates and Increased Early Miscarriage Rates Following IVF/ICSI Treatment and Fresh Embryo Transfer | 27.3 | 0 | 2 |
| Prospective randomized trial comparing efficacy of letrozole step-up protocol with letrozole plus gonadotropins for controlled ovarian stimulation and intrauterine insemination in patients with unexplained infertility | 27.3 | 0 | 2 |
| Second-generation preimplantation genetic testing for aneuploidy in assisted reproduction: a SWOT analysis | 27.3 | 0 | 2 |
| Luteal-phase progesterone supplementation in non-IVF treatment: a survey of physicians providing infertility treatment | 27.3 | 0 | 2 |
| Oocyte exposure to supraphysiological estradiol during ovarian stimulation increased the risk of adverse perinatal outcomes after frozen-thawed embryo transfer: a retrospective cohort study | 27.3 | 0 | 2 |
| A quality management approach to controlled ovarian stimulation in assisted reproductive technology: the "Fischer protocol" | 27.3 | 0 | 2 |
| Influence of surgical evacuation on pregnancy outcomes of subsequent embryo transfer cycle following miscarriage in an initial IVF cycle: a retrospective cohort study | 27.3 | 0 | 2 |
| Effect of embryo transfer difficulty on live birth rates studied in vitrified-warmed euploid blastocyst transfers | 27.3 | 0 | 2 |
| Ovarian stimulation for preimplantation genetic testing | 27.3 | 0 | 2 |
| Live birth rates and perinatal outcomes when all embryos are frozen compared with conventional fresh and frozen embryo transfer: a cohort study of 337,148 in vitro fertilisation cycles | 27.3 | 0 | 2 |
| Live birth rates after different endometrial preparation methods in frozen cleavage-stage embryo transfer cycles: a randomized controlled trial | 27.3 | 0 | 2 |
| Live birth rates with a freeze-only strategy versus fresh embryo transfer: secondary analysis of a randomized clinical trial | 27.3 | 0 | 2 |
| Vaginal cuff dehiscence following controlled ovarian stimulation recognized during egg retrieval | 27.3 | 0 | 2 |
| Defining thresholds for abnormal premature progesterone levels during ovarian stimulation for assisted reproduction technologies | 27.3 | 0 | 2 |
| Abstracts presented at the 2019 Foundation for Reproductive Medicine Conference on Translational Reproductive Biology and Clinical Reproductive Endocrinology | 27.3 | 0 | 2 |
| The ethics of fertility treatment for same-sex male couples: Considerations for a modern fertility clinic | 27.3 | 0 | 2 |
| [Medically Assisted Reproduction in Natural Cycle: Outcome Evaluation of a Reproductive Medicine Department] | 27.3 | 0 | 2 |
| Corticosteroids Prior to Embryo Transfer in Assisted Reproduction in Women with Crohn's Disease and Ulcerative Colitis - A Nationwide Cohort Study | 27.3 | 0 | 2 |
| Ovarian stimulation protocols in assisted reproductive technology: an update | 27.3 | 0 | 2 |
| Preimplantation genetic testing for aneuploidy: a comparison of live birth rates in patients with recurrent pregnancy loss due to embryonic aneuploidy or recurrent implantation failure | 27.3 | 0 | 2 |
| A counterintuitive lesson in family planning? Patience first: taking a "gap year" after live birth from assisted reproductive technology before frozen embryo transfer is performed | 27.3 | 0 | 2 |
| Prediction of live birth and cumulative live birth rates in freeze-all-IVF treatment of a general population | 27.3 | 0 | 2 |
| Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review | 27.3 | 0 | 2 |
| Conservative treatment versus surgical excision of ovarian dermoid cysts: Impact on ovarian stimulation and IVF cycle success | 27.3 | 0 | 2 |
| Different anti-Műllerian hormone (AMH) levels respond to distinct ovarian stimulation methods in assisted reproductive technology (ART): Clues to better ART outcomes | 27.3 | 0 | 2 |
| Measuring serum estradiol and progesterone one day prior to frozen embryo transfer improves live birth rates | 27.3 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer | 27.3 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer-Reply | 27.3 | 0 | 2 |
| Fertility Related Quality of Life, Gonadal Function and Erectile Dysfunction in Male Partners of Couples with Unexplained Infertility | 27.3 | 0 | 2 |
| [Cumulative live birth rates after frozen embryo transfer and fresh embryo transfer with oocyte numbers more than 15] | 27.3 | 0 | 2 |
| Transfer of embryos with positive results following preimplantation genetic testing for monogenic disorders (PGT-M): experience of two high-volume fertility clinics | 27.3 | 0 | 2 |
| Isthmocele and ovarian stimulation for IVF: considerations for a reproductive medicine specialist | 27.3 | 0 | 2 |
| Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology | 27.3 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion | 27.3 | 0 | 2 |
| Could fertility clinics offer a sizable improvement of live birth rates by maturing post-GVBD oocytes in vitro? | 27.3 | 0 | 2 |
| A Chinese practice guideline of the assisted reproductive technology strategies for women with advanced age | 27.3 | 0 | 2 |
| Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations | 27.3 | 0 | 2 |
| Endometrial thickness on the day of embryo transfer is a poor predictor of IVF treatment outcome | 27.3 | 0 | 2 |
| Analysis of embryo quality with luteal phase ovarian stimulation after failed in vitro fertilization-embryo transfer with long or ultra-long protocol | 27.3 | 0 | 2 |
| Preimplantation genetic testing for aneuploidy: a comparison of live birth rates in patients with recurrent pregnancy loss due to embryonic aneuploidy or recurrent implantation failure | 27.3 | 0 | 2 |
| Lower prevalence of non-cavity-distorting uterine fibroids in patients with polycystic ovary syndrome than in those with unexplained infertility | 27.3 | 0 | 2 |
| Impact of Female Obesity on Cumulative Live Birth Rates in the First Complete Ovarian Stimulation Cycle | 27.3 | 0 | 2 |
| Live Birth Rates in Poor Responders' Group after Previous Treatment with Autologous Platelet-Rich Plasma and Low Dose Ovarian Stimulation Compared with Poor Responders Used Only Low Dose Ovarian Stimulation Before in Vitro Fertilization | 27.3 | 0 | 2 |
| The Impact of Traditional Medicine-Based Lifestyle and Diet on Infertility Treatment in Women Undergoing Assisted Reproduction: A Randomized Controlled Trial | 27.3 | 0 | 2 |
| No specific adverse pregnancy outcome in singleton pregnancies after assisted reproductive technology (ART) for unexplained infertility | 27.3 | 0 | 2 |
| Impact of Melatonin Supplementation in Women with Unexplained Infertility Undergoing Fertility Treatment | 27.3 | 0 | 2 |
| Gonadotropins versus oral ovarian stimulation agents for unexplained infertility: a systematic review and meta-analysis | 27.3 | 0 | 2 |
| Embryo transfer associated with hormone replacement therapy cycles using assisted reproductive technology increases placenta accreta spectrum | 27.3 | 0 | 2 |
| Transvaginal ovarian drilling followed by controlled ovarian stimulation from the next day improves ovarian response for the poor responders with polycystic ovary syndrome during IVF treatment: a pilot study | 27.3 | 0 | 2 |
| Evaluation of the effect of the elective blastocyst-stage embryo transfer and freezing strategy on the abandonment of frozen embryos under the Taiwan National Assisted Reproduction Act | 27.3 | 0 | 2 |
| Spontaneous Conception during In Vitro Fertilization prior to Embryo Transfer without the Opportunity for Preimplantation Genetic Testing | 27.3 | 0 | 2 |
| Patient perceptions and understanding of treatment instructions for ovarian stimulation during infertility treatment | 27.3 | 0 | 2 |
| Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population | 27.3 | 0 | 2 |
| Progestins versus GnRH analogues for pituitary suppression during ovarian stimulation for assisted reproductive technology: a systematic review and meta-analysis | 27.3 | 0 | 2 |
| Cumulative Live Birth Rates According to Maternal Body Mass Index After First Ovarian Stimulation for in vitro Fertilization: A Single Center Analysis of 14,782 Patients | 27.3 | 0 | 2 |
| Endometrial volume measured on the day of embryo transfer is not associated with live birth rates in IVF: a prospective study and review of the literature | 27.3 | 0 | 2 |
| A Randomized Trial Comparing the Live Birth Rate of Immediate Versus Delayed Frozen Embryo Transfer (FET) Following a Freeze-all Strategy | 27.3 | 0 | 2 |
| Trends in Live Birth Rates Attributable to Assisted Reproductive Technology in British Columbia | 27.3 | 0 | 2 |
| College of American Pathologists and American Society for Reproductive Medicine accreditation of assisted reproductive technology (ART) laboratories is associated with a decrease in take home baby rates of reporting ART laboratories | 27.3 | 0 | 2 |
| Erratum to: Relationship between oxidative stress and clinical pregnancy in assisted reproductive technology treatment cycles | 27.3 | 0 | 2 |
| Guidelines on the number of embryos transferred | 27.3 | 0 | 2 |
| No effect of ovarian stimulation and oocyte yield on euploidy and live birth rates: an analysis of 12 298 trophectoderm biopsies | 27.3 | 0 | 2 |
| [Elective single embryo transfer in assisted reproduction] | 27.3 | 0 | 2 |
| When is the optimal timing of frozen embryo transfer after controlled ovarian stimulation? | 27.3 | 0 | 2 |
| Does a hyperechogenic endometrial mass in the uterus during controlled ovarian stimulation affect assisted reproductive technology cycle outcomes? | 27.3 | 0 | 2 |
| Virtual Reality Use in Assisted Reproductive Technology | 27.3 | 0 | 2 |
| Intrauterine insemination performance characteristics and post-processing total motile sperm count in relation to live birth for couples with unexplained infertility in a randomised, multicentre clinical trial | 27.3 | 0 | 2 |
| Changes in the levels of selected metabolites in the culture medium as a possible tool for the embryo selection in assisted reproduction | 27.3 | 0 | 2 |
| [Preparation for assisted reproductive technology in the course of infertility treatment in the female soldiers] | 27.3 | 0 | 2 |
| Value of sperm acrosin activity detection in selecting the method of assisted reproduction for patients with unexplained infertility | 27.3 | 0 | 2 |
| Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology | 27.3 | 0 | 2 |